Newsgather
BackRFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves
RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves
NEWS
CNBC US Markets4/16/2026BusinessUnited States

RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves

Font size

Hims may have a chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.

Continue reading on CNBC US Markets
This article was originally published by CNBC US Markets.

Related Stories